Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / UCHL1



This biomarker is also known as:
  • ubiquitin C-terminal hydrolase,
  • Ubiquitin thioesterase L1,
  • Uch-L1,
  • PGP9.5,
  • UCH-L1,
  • PGP95,
  • PARK5,
  • Neuron cytoplasmic protein 9.5,
  • PGP 9.5,
  • ubiquitin carboxyl-terminal esterase L1 (ubiquitin thiolesterase),
  • ubiquitin carboxyl-terminal hydrolase isozyme L1,

View in BioMuta


PGP9.5, also called Ubiquitin-protein hydrolase (UCHL1), is a member of a gene family whose products hydrolyze small C-terminal adducts of ubiquitin to generate the ubiquitin monomer. Expression of UCHL1 is highly specific to neurons and to cells of the diffuse neuroendocrine system and their tumors. This enzyme is a thiol protease that recognizes and hydrolyzes a peptide bond at the C-terminal glycine of ubiquitin. Oxidation of Met-1, Met-6, Met-12, Met-124 and Met-179 to methionine sulfoxide, and oxidation of Cys-220 to cysteine sulfonic acid have been observed in brains from Alzheimer disease (AD) and Parkinson disease (PD) patients. PGP9.5 has been proposed as a marker with a potential role in carcinogenesis.


QA State: Accepted
Type: Protein
Short Name:


The following organs have data associated with this biomarker…



Phase: Three
QA State: Under Review


PGP9.5 antigens were found to be targets of autoantibodies in newly diagnosed subjects with lung cancer. PGP9.5 is also highly expressed in non-small lung cancer cell line H157, having high invasive potential, and the expression of PGP9.5 in tumor cells enhances their invasive potential in vitro and in vivo.

Performance Comment

The findings of this study show autoantibodies to UCHL1 (PGP9.5) may have diagnostic utility in conjunction with an imaging modality in symptomatic patients.

Supporting Study Data

The following studies/protocols provide evidence supporting UCHL1 indications for the Lung…

Validation of Protein Markers for Lung Cancer Using CARET Sera and Proteomics Techniques

1.1 To validate the finding from pilot studies with CARET sera of autoantibodies to annexins I and II and PGP9.5 as potential biomarkers for lung cancers before the clinical diagnosis, evaluating sensitivity and specificity by time before diagnosis, treatment arm, gender, histologic type, and smoking status. 1.2 To determine whether a pattern of occurrence of autoantibodies in lung cancer sera may be diagnostic of lung cancer that is not dependent on the occurrence of any particular autoantibody. 1.3 To compare the findings for individual biomarker candidates and combinations of biomarker candidates in participants who were current smokers versus former smokers.

View more about this study
Biomarker Characteristics Summary
Notes Sensitivity Specificity Prevalence NPV PPV Specific Assay Type
Individual sera collected from 85 subjects within a year prior to a diagnosis of lung cancer and 85 matched controls from the CARET cohort were used in this analysis. Sam Hanash laboratory. 44.0 51.0 N/A N/A N/A
Individual sera collected from 85 subjects within a year prior to a diagnosis of lung cancer and 85 matched controls from the CARET cohort were used in this analysis. Sam Hanash laboratory. 82.0 26.0 N/A N/A N/A
Decision Rule


Additional Study-Specific Protocols
Study-Specific Publications
Study-Specific Resources

Organ-Specific Protocols

No organ-specific protocols defined.

Organ-Specific Publications

Organ-Specific Resources

No organ-specific resources defined.


No associated studies or protocols found.

2016 EDRN PI Orientation

The New and Continuing EDRN Principal Investigator Orientation will take place March 14–15, 2016 in Bethesda, Maryland.

Announcement 11/05/2015

Thank you to everyone who made the 29th EDRN Steering Committee Meeting a success. The orientation for new and continuing EDRN PIs will be held Monday-Tuesday, March 14-15, 2016, on the NCI campus. More information will be available later this autumn.

Announcement 06/30/2015

A funding opportunity for a new pancreatic cancer initiative, called The Pancreatic Cancer Detection Consortium (U01), has been released. For more information, please go to /grants/guide/ pa-files/ PAR-15-289.html.